| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3391157 | Seminarios de la Fundación Española de Reumatología | 2008 | 6 Pages |
Abstract
IV CYC is the only drug for which long-term data on LN is available. As evidence of other therapies such as MMF accumulates, however, IV CYC might no longer be considered the standard treatment for LN.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Julio RamÃrez GarcÃa, Paula Cejas Cáceres, Esteban Rubio Romero, Juan Bautista Povedano Gómez, Alicia GarcÃa López,